ETHAN - ET for Male BC

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib

Trial Details

NCT ID
NCT05501704
Phase
PHASE2
Sponsor
Jose Pablo Leone
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Tamoxifen
  • Anastrozole
  • Degarelix
  • Abemaciclib
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Men aged 18 years or older, with diagnosis of invasive breast cancer who have not undergone surgical resection of the primary tumor and axillary no…
  • Stage I, II, or III per American Joint Committee on Cancer (AJCC) staging 8th edition (112).
  • Breast cancer must be hormone receptor-positive and HER2-negative according to definition below assessed by local pathology.
  • Hormone receptor-positive is defined as: positivity for at least one of the hormone receptors (estrogen receptor \[ER\] or progesterone receptor \[…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →